In-Depth Examination Of 6 Analyst Recommendations For IGM Biosciences
Portfolio Pulse from Benzinga Insights
IGM Biosciences (NASDAQ:IGMS) has been analyzed by 6 analysts over the past three months, showing a range of perspectives from bullish to bearish. The average 12-month price target is $16.17, with a high of $21.00 and a low of $12.00. Recent ratings include 'Neutral' and 'Outperform' with price targets ranging from $12.00 to $21.00. The company's financial performance shows challenges in revenue growth and returns on equity and assets, but it maintains a balanced debt approach.
May 24, 2024 | 2:01 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
IGM Biosciences has received mixed analyst ratings with an average 12-month price target of $16.17. The company's financial performance shows challenges in revenue growth and returns on equity and assets, but it maintains a balanced debt approach.
The mixed analyst ratings and the average price target of $16.17 suggest a neutral short-term impact on the stock. Financial challenges such as revenue decline and low ROE/ROA are balanced by a stable debt-to-equity ratio, leading to a neutral outlook.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100